The purpose of this study is to evaluate the safety of atezolizumab, a medication currently used to treat various cancers, in individuals who have mild or moderate idiopathic pulmonary fibrosis (IPF). The study also aims to determine whether the medication can stop the progression of IPF. In addition, researchers will examine whether a biomarker test is helpful in deciding which patients are most likely to benefit from the study drug. A biomarker is a biological molecule found in blood, other body fluids or tissue and may be a sign of a condition or disease; it can be used to predict an individual's response to a specific treatment. The use of atezolizumab in this study is investigational.
What is the full name of this clinical trial?
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of Atezolizumab in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis
Alain Mita, Paul Noble